Literature DB >> 7768246

EMEA and the new pharmaceutical procedures for Europe. European Medicines Evaluation Agency.

D B Jefferys1, K H Jones.   

Abstract

The regulation of medicines throughout Europe has undergone significant change since the first pharmaceutical Directive in 1965. 1995 will bring the next major stage in this evolution with the introduction of the so-called "Future System proposals". These will see the creation of the EMEA (the European Medicines Evaluation Agency), the introduction of a Centralized Procedure, applicable to a small number of innovative drugs, and a Decentralized Procedure, based on mutual recognition of licences granted by existing control authorities in other EC countries. The regulation of medicines in the United Kingdom has also changed considerably since the establishment of the Medicines Control Agency in 1989. This article looks at the new licensing arrangements for Europe and the development of medicines control in the UK over the last few years.

Mesh:

Year:  1995        PMID: 7768246     DOI: 10.1007/BF00193696

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  1 in total

Review 1.  The review of medicines in the United Kingdom.

Authors:  K Winship; D Hepburn; D H Lawson
Journal:  Br J Clin Pharmacol       Date:  1992-06       Impact factor: 4.335

  1 in total
  4 in total

1.  Should the philosophy of postmarketing surveillance in the US be redefined?

Authors:  J Soto; J A Sacristan
Journal:  Pharmacoeconomics       Date:  1995-08       Impact factor: 4.981

2.  Regulating medicines in Croatia: five-year experience of Agency for Medicinal Products and Medical Devices.

Authors:  Sinisa Tomić; Anita Filipović Sucić; Ana Plazonić; Rajka Truban Zulj; Viola Macolić Sarinić; Branka Cudina; Adrijana Ilić Martinac
Journal:  Croat Med J       Date:  2010-04       Impact factor: 1.351

Review 3.  Ocular medicines in children: the regulatory situation related to clinical research.

Authors:  Filomena Fortinguerra; Antonio Clavenna; Maurizio Bonati
Journal:  BMC Pediatr       Date:  2012-01-20       Impact factor: 2.125

4.  The timing of introduction of pharmaceutical innovations in seven European countries.

Authors:  Ragnar Westerling; Marcus Westin; Martin McKee; Rasmus Hoffmann; Iris Plug; Grégoire Rey; Eric Jougla; Katrin Lang; Kersti Pärna; José L Alfonso; Johan P Mackenbach
Journal:  J Eval Clin Pract       Date:  2014-04-22       Impact factor: 2.431

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.